Personalis Rallies Following $50 Million Investment from Merck, Extended Agreement With Moderna

MT Newswires Live12-19

Personalis (PSNL) was surging early in Thursday's regular trading session, climbing almost 26%, after the cancer genomic testing and analytics company disclosed a $50 million investment from Merck (MRK) and a multiyear extension agreement with Moderna (MRNA).

Merck will buy around 14 million Personalis shares at $3.56 apiece, matching Wednesday's closing price and providing Merck with roughly 16.5% of the company's outstanding stock, Personalis said.

Personalis said it also extended its collaboration with Moderna to use the company's ImmunoID NeXT tumor-profiling platform to assist with the testing of V940/mRNA-4157 individualized neoantigen therapy being developed jointly by Moderna and Merck. Financial details of the extended agreement weren't provided.

Price: 4.47, Change: +0.91, Percent Change: +25.56

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment